feelings of euphoria/mood enhancement; improved cognitive function; fatigue; muscle soreness; tension; joint pain; thirst; the injection site pain started within 1 hr.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 03Nov2022 at 15:15 as dose 5 (booster), single (Lot number: GH9697) at the age of 67 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "osteoarthritis" (unspecified if ongoing); "hypertension" (unspecified if ongoing). Concomitant medication(s) included: FLU VACCINE VII taken for immunisation, on 23Oct2022 as dose 1, single, flu vaccine senior dose; LISINOPRIL; MOTRIN [IBUPROFEN]. Vaccination history included: BNT162b2 (DOSE 4 (BOOSTER), SINGLE, Batch/Lot No: FK9893, Location of injection: Arm Left, Vaccine Administration Time: 04:00 PM), administration date: 05Apr2022, when the patient was 67-year-old, for COVID-19 immunization; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Batch/Lot No: FC3184, Location of injection: Arm Right, Vaccine Administration Time: 05:00 PM), administration date: 27Sep2021, when the patient was 66-year-old, for COVID-19 immunization; BNT162b2 (DOSE 2, SINGLE, Batch/Lot No: EP7534, Location of injection: Arm Right, Vaccine Administration Time: 01:15 PM), administration date: 22Mar2021, when the patient was 66-year-old, for COVID-19 immunization; BNT162b2 (DOSE 1, SINGLE, Batch/Lot No: EN6201, Location of injection: Arm Left, Vaccine Administration Time: 08:15 AM), administration date: 26Feb2021, when the patient was 66-year-old, for COVID-19 immunization. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 03Nov2022 at 16:15, outcome "recovered" (04Nov2022 at 14:15), described as "the injection site pain started within 1 hr."; FATIGUE (non-serious) with onset 03Nov2022 at 22:00, outcome "recovered" (04Nov2022 at 20:00); ARTHRALGIA (non-serious) with onset 03Nov2022 at 22:00, outcome "recovered" (04Nov2022 at 20:00), described as "joint pain"; MYALGIA (non-serious) with onset 03Nov2022 at 22:00, outcome "recovered" (04Nov2022 at 20:00), described as "muscle soreness"; TENSION (non-serious) with onset 03Nov2022 at 22:00, outcome "recovered" (04Nov2022 at 20:00); THIRST (non-serious) with onset 03Nov2022 at 22:00, outcome "recovered" (04Nov2022 at 20:00); EUPHORIC MOOD (non-serious) with onset 04Nov2022 at 07:15, outcome "recovered", described as "feelings of euphoria/mood enhancement"; COGNITIVE DISORDER (non-serious) with onset 04Nov2022 at 07:15, outcome "recovered", described as "improved cognitive function". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of euphoric mood, fatigue, myalgia, tension, arthralgia, thirst, vaccination site pain, cognitive disorder.  Additional information: The adverse events were initial fatigue, muscle soreness, tension, joint pain with some thirst within first 24 hours. The injection site pain started within 1 hour and other symptoms followed but disappeared 22 hours later. However adverse symptoms were temporary, and patient noticed mood enhancement, improved cognitive function, feelings of euphoria 16 hours after injection. The patient had no known allergies. In Mar2022 (post vaccination with third dose), the patient underwent covid test (Nasal Swab) and the results was negative.